Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.42 |
| ▸ | IKBKB | O14920 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972587 | 1.00 | CD44 (0.42) | CD44IKBKBDRD2DRD3PNMT | |
| Hydrochloric Acid SCHEMBL621622 | 0.98 | CD44 (0.41) | CD44IKBKBDRD2DRD3PNMT | |
| Hydrochloric Acid SCHEMBL30453968 | 0.98 | CD44 (0.41) | CD44IKBKBDRD2DRD3PNMT | |
| SCHEMBL620774 | 0.86 | IKBKB (0.44) | CD44IKBKBDRD2DRD3RAF1 | |
| SCHEMBL29587158 | 0.81 | CD44 (0.61) | CD44DRD2DRD3PNMTMAOB | |
| SCHEMBL327075 | 0.81 | CD44 (0.61) | CD44DRD2DRD3PNMTMAOB | |
| SCHEMBL3052029 | 0.81 | PNMT (0.61) | CD44PNMTMAOBHTR2CADRA2A | |
| Hydrochloric Acid SCHEMBL29586475 | 0.79 | CD44 (0.59) | CD44DRD2DRD3PNMTMAOB | |
| Hydrochloric Acid SCHEMBL1124513 | 0.79 | CD44 (0.59) | CD44DRD2DRD3PNMTMAOB | |
| Hydrochloric Acid SCHEMBL2258194 | 0.79 | PNMT (0.59) | CD44PNMTMAOBHTR2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939668-B2 | Ruthenium complexes as catalysts for metathesis reactions | ROCHE PALO ALTO LLC (US) | 2011-05-10 | — | — | US | claimed |
| US-20090275714-A1 | New Ruthenium Complexes as Catalysts for Metathesis Reactions | ROCHE PALO ALTO LLC | 2009-11-05 | — | — | US | claimed |
| US-4777181-A | ANTIDIABETIC AGENTS | BEIERSDORF AG (DE) | 1988-10-11 | — | — | US | claimed |
| EP-0228640-A1 | Substituted 4-fluoro-isoindolines, method for their preparation and their use as well as compositions containing them | Beiersdorf Aktiengesellschaft (DE) | 1987-07-15 | — | — | EP | claimed |
| EP-4707279-A1 | SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUND AS PHARMACEUTICAL FOR TREATMENT OR PREVENTION OF COVID-19 | Albius Sciences Beta Pte. Ltd. (SG) | 2026-03-11 | — | — | EP | disclosed |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | RECOVERY THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| CN-117157069-A | Compounds, compositions and methods for modulating FGF activity | 康复治疗公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230365567-A1 | COMPOUNDS | Esfam Biotech Pty Ltd (AU) | 2023-11-16 | — | — | US | disclosed |
| CN-116987021-A | Novel isoindoline derivative with anti-tumor effect as well as preparation method and application thereof | 北京中医药大学 | 2023-11-03 | — | — | CN | disclosed |
| CN-116829558-A | Compounds of formula (I) | 艾斯法姆生物技术股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-4238962-A1 | METHOD FOR PRODUCING DIIMINOPYRROLE COMPOUND | Godo Shigen Co., Ltd. (JP) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023116779-A1 | DIALKYNE COMPOUND AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-5026856-A | Bactericides | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1991-06-25 | — | — | US | disclosed |
| EP-0343560-A2 | Isoindoline derivative | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1989-11-29 | — | — | EP | disclosed |
| US-4777181-A | ANTIDIABETIC AGENTS | BEIERSDORF AG (DE) | 1988-10-11 | — | — | US | disclosed |
| US-4777181-A | ANTIDIABETIC AGENTS | BEIERSDORF AG (DE) | 1988-10-11 | — | — | US | disclosed |
| US-4777181-A | ANTIDIABETIC AGENTS | BEIERSDORF AG (DE) | 1988-10-11 | — | — | US | disclosed |
| EP-0228640-A1 | Substituted 4-fluoro-isoindolines, method for their preparation and their use as well as compositions containing them | Beiersdorf Aktiengesellschaft (DE) | 1987-07-15 | — | — | EP | disclosed |
| EP-0228640-A1 | Substituted 4-fluoro-isoindolines, method for their preparation and their use as well as compositions containing them | Beiersdorf Aktiengesellschaft (DE) | 1987-07-15 | — | — | EP | disclosed |
| EP-0228640-A1 | Substituted 4-fluoro-isoindolines, method for their preparation and their use as well as compositions containing them | Beiersdorf Aktiengesellschaft (DE) | 1987-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365567-A1 | COMPOUNDS | CD81, CD47, CD59 | CD44 152/4885IKBKB 2216/4885DRD2 1402/4885 |
| US-20240174631-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FGF ACTIVITY | FGF1, FGF2, FGFR1 | CD44 3337/4885IKBKB 3761/4885DRD2 4709/4885 |
| US-20090275714-A1 | New Ruthenium Complexes as Catalysts for Metathesis Reactions | HABP2, CYP3A7, ACE | CD44 4611/4885IKBKB 2179/4885DRD2 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.